lifecycle management strategy

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...

By Michelle Vitko,Research Analyst Recently, I wrote a piece on the need for portfolio management teams to plan well ahead of patent expiry to maximize the number of tactics available to them to extend the lifecycle of the products in their portfolio....

By Ryan McGuire,Senior Research Analyst This is the third installment in a blog series focusing on counter-generic strategies. You can read part 1 about the patent cliff and the second part on patent litigation. Under the FDA's Modernization Act Continue...

By Jeremy Spivey,Senior Research Analyst Preliminary survey results from our ongoing portfolio management study have already revealed some interesting details. Among them: * Government payer reimbursement rates for products are Continue reading “Portfolio...

By Ryan McGuire,Senior Research Analyst This is the second installment in a blog series focusing on counter-generic strategies. Read the first part here. Litigation is a natural response for pharmaceutical and biotechnology companies that find their...

As the expiration of Pfizer's Lipitor exclusivity draws closer, many in the pharmaceutical industry are trying to decipher what the final distribution of statin market share will be. Two factors are contributing to lingering uncertainty, however, making the market...

This is the first entry in a series that will focus on countering generic competition and preserving pharmaceutical brand revenue. Much has been made about the slew of drugs that face the loss of patent protection in 2011. In all, experts estimate that $30...

The Biologics Price Competition and Innovation Act (BPCI), passed by Congress in 2009, was intended by its sponsors to reign in the rising healthcare cost. Two years later the FDA still has not established complete guidance on an abbreviated pathway for biosimilars...

Counter-generics tactics will evolve, but not radically change, between now and 2014, according to our latest portfolio management research. There are some favored tactics that companies plan to use more frequently going forward than they have up until now. As...

Cutting Edge Information’s study finds that short-term strategies are giving way to long-term strategies. Short-term strategies, such as patent litigation and defensive pricing, have been the most popular counter-generics tactics for pharmaceutical brand teams...